{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:42:03Z","timestamp":1791999723021,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013795","name":"Fujian Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.anndiagpath.2025.152481","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T02:43:15Z","timestamp":1744425795000},"page":"152481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["PD - L1 (SP263) expression correlates with pathological aggressive parameters in prostate cancer"],"prefix":"10.1016","volume":"78","author":[{"given":"Xiaopeng","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.anndiagpath.2025.152481_bb0005","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology[J]","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"11","key":"10.1016\/j.anndiagpath.2025.152481_bb0010","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.3390\/cells10113166","article-title":"What do we have to know about PD-L1 expression in prostate cancer? a systematic literature review. Part 1: focus on immunohistochemical results with discussion of pre-analytical and interpretation variables[J]","volume":"10","author":"Palicelli","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.anndiagpath.2025.152481_bb0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system[J]","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"22","key":"10.1016\/j.anndiagpath.2025.152481_bb0020","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-17-0807","article-title":"Expression of PD-L1 in hormone-nave and treated prostate Cancer patients receiving neoadjuvant Abiraterone acetate plus prednisone and leuprolide[J]","volume":"23","author":"Calagua","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.anndiagpath.2025.152481_bb0025","first-page":"1001","article-title":"Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China[J]","volume":"43","author":"Tumor Pathology Committee of Chinese Anti-Cancer Association, Expert Committee on Urothelial Carcinoma of Chinese Society of Clinical Oncology","year":"2021","journal-title":"Chin J Oncol"},{"issue":"13","key":"10.1016\/j.anndiagpath.2025.152481_bb0030","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-19-3372","article-title":"T-cell infiltration and adaptive Treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer[J]","volume":"26","author":"Obradovic","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.anndiagpath.2025.152481_bb0035","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/apm.12970","article-title":"PD-L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate[J]","volume":"127","author":"Lindh","year":"2019","journal-title":"Apmis"},{"issue":"6","key":"10.1016\/j.anndiagpath.2025.152481_bb0040","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.ajpath.2018.02.014","article-title":"Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer[J]","volume":"188","author":"Haffner","year":"2018","journal-title":"Am J Pathol"},{"issue":"14","key":"10.1016\/j.anndiagpath.2025.152481_bb0045","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.7150\/thno.21471","article-title":"Genomic analysis of tumor microenvironment immune types across 14 solid Cancer types: immunotherapeutic implications[J]","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.anndiagpath.2025.152481_bb0050","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/jclinpath-2018-205404","article-title":"Immune infiltrates and PD-L1 expression in treatment-na\u00efve acinar prostatic adenocarcinoma: an exploratory analysis[J]","volume":"71","author":"Hahn","year":"2018","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.anndiagpath.2025.152481_bb0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.humpath.2018.07.024","article-title":"Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head\/neck carcinomas, antibody clones, and tissue types[J]","volume":"82","author":"Wang","year":"2018","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2025.152481_bb0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12957-021-02325-z","article-title":"The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer[J]","volume":"19","author":"He","year":"2021","journal-title":"World J Surg Oncol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2025.152481_bb0065","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1158\/1078-0432.CCR-15-2042","article-title":"The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer[J]","volume":"22","author":"Gevensleben","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.anndiagpath.2025.152481_bb0070","first-page":"159","article-title":"PD-L1 instead of PD-1 status is associated with the clinical features in human primary prostate tumors[J]","volume":"7","author":"Xian","year":"2019","journal-title":"Am J Clin Exp Urol"},{"issue":"11","key":"10.1016\/j.anndiagpath.2025.152481_bb0075","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.3390\/cells10113165","article-title":"What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 2: clinic\u2013pathologic correlations[J]","volume":"10","author":"Palicelli","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.anndiagpath.2025.152481_bb0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2016.05.001","article-title":"Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status[J]","volume":"97","author":"Cha","year":"2016","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.anndiagpath.2025.152481_bb0085","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 regulation by p53 via miR-34[J]","volume":"108","author":"Cortez","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.anndiagpath.2025.152481_bb0090","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.2147\/OTT.S209484","article-title":"Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer[J]","volume":"12","author":"Zeng","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"32","key":"10.1016\/j.anndiagpath.2025.152481_bb0095","first-page":"143","article-title":"Tumor PD-L1 expression is detected in a significant subset of high-risk localized and metastatic prostate cancer but is rare in ductal subtype. Abstracts from USCAP 2019: genitourinary pathology (including renal tumors) (776\u2013992)[J]","author":"Shaw","year":"2019","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2025.152481_bb0100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jnci\/djy141","article-title":"The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target[J]","volume":"111","author":"Zhao","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.anndiagpath.2025.152481_bb0105","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/CJI.0000000000000287","article-title":"PD-L1 expression in de novo metastatic castration-sensitive prostate cancer[J]","volume":"42","author":"Iacovelli","year":"2019","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.anndiagpath.2025.152481_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eururo.2022.08.005","article-title":"Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort a study [J]","volume":"83","author":"Yu","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2025.152481_bb0115","doi-asserted-by":"crossref","first-page":"25447","DOI":"10.31083\/FBL25447","article-title":"A primer on the role of TP53 mutation and targeted therapy in endometrial cancer[J]","volume":"30","author":"Zhang","year":"2025","journal-title":"Front Biosci (Landmark Ed)"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913425000462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913425000462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:40:00Z","timestamp":1762364400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913425000462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":23,"alternative-id":["S1092913425000462"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2025.152481","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD - L1 (SP263) expression correlates with pathological aggressive parameters in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2025.152481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152481"}}